MHRA

Recall 1280.jpg bookmark_icon_off

Quadrant recall batch of mefenamic acid tablets

Batch number 107082 found to have a defective layer of film coating.

1 Min Article

Recall 1280.jpg bookmark_icon_off
Public health

MHRA recalls two drugs in two days

A batch of sodium bicarbonate 1.26 per cent solution for infusion and Paroxetine 40mg film coated tablets were recalled.

1 Min Article

overactive bladder, summary.jpg bookmark_icon_off
Women's health

Mixed reaction to proposed oxybutynin POM to P switch

Some pharmacists have criticised a proposal to reclassify the drug for overactive bladder in women.

2 Min Article

pregabalin summary.jpg bookmark_icon_off
Medication safety

MHRA highlights Nordic pregabalin risk study

Slightly higher risk of major congenital malformations when pregabalin is taken in pregnancy.

1 Min Article

pregabalin summary.jpg bookmark_icon_off
Medication safety

MHRA highlights Nordic pregabalin risk study

Slightly higher risk of major congenital malformations when pregabalin is taken in pregnancy.

1 Min Article

Justice 1280.jpg bookmark_icon_off
Legal

Syri fined after supplying under-strength medicine to child

Company ordered to pay over £50,000 and more than £100,000 in costs after specials manufacturing error

1 Min Article

menopause summary.jpg bookmark_icon_off
Women's health

Government proposes POM to P switch for HRT product

MHRA launches a proposal on reclassifying the HRT vaginal tablet Gina 10.

1 Min Article

Haloperidol 1280 x 720.jpg bookmark_icon_off
Clinical

MHRA reminder of adverse effects of haloperidol in the elderly

MHRA warns of increased risk of adverse neurological and cardiac effects in elderly patients on haloperidol.

1 Min Article

Justice 1280.jpg bookmark_icon_off
GPhC

Pharmacist jailed for unlawful CD supply is struck off by GPhC

Balkeet Singh Khaira supplied controlled drugs worth more than £1m on the black market.

2 Min Article

molnupiravir tablets 1280x720.jpg bookmark_icon_off
Clinical

First oral antiviral for Covid-19 approved by MHRA

Molnupiravir reduces risk of hospitalisation or death for at-risk adults with mild to moderate Covid-19 by 50 per cent.

1 Min Article

Loading